文献速递间质性肺疾病

低用力肺活量与生理学稳定的非IPF间质性肺疾病不良预后相关

Low forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease.
PubMed 文献 · Eur Respir J · 2026-01-22

在确诊后第一年预测FVC下降<5个百分点的非IPF间质性肺疾病患者中,基线低FVC仍与肺移植或死亡风险升高相关;仅以进展性肺纤维化标准评估可能漏判这些「稳定」高危患者,应早期识别并加强监测。

要点

  • 非IPF间质性肺疾病患者即使FVC年下降<5个百分点,基线低FVC仍提示预后不良。
  • 现行进展性肺纤维化标准聚焦后续变化,可能漏判基线肺功能已严重受损的高危患者。
  • 对生理学稳定但基线低FVC者应早期标记并考虑密切监测。

核心结论

  • 在非IPF间质性肺疾病且第一年FVC预测下降<5个百分点的患者中,基线低FVC与肺移植或死亡风险升高相关。

研究设计与样本

  • 基于Eur Respir J发表的研究,纳入非IPF间质性肺疾病患者,分析确诊后第一年FVC预测下降<5个百分点者的基线FVC与肺移植或死亡的关联。

主要发现

  • 基线低FVC与肺移植或死亡风险升高相关,即使在第一年FVC预测下降<5个百分点的「稳定」患者中亦然。

关键数值与推荐

  • 进展性肺纤维化定义为12个月内以下三项中至少两项:症状加重、肺功能下降、新发或扩展的影像学异常。
  • 研究限定第一年FVC预测下降<5个百分点。

临床怎么用

  • 对非IPF间质性肺疾病患者,除动态监测FVC变化外,应关注基线FVC水平以识别高危患者。
  • 对基线低FVC但后续FVC稳定的患者,考虑早期加强监测和及时启动治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients who present with reduced FVC, yet show no further FVC decline, still face poor outcomes. This demonstrates how progression-based criteria can misclassify these “stable” cases and highlights the importance of flagging them early. https://bit.ly/4oAnTgw Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Imai R, Bermea RS, Zhao SH, et al. Low forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease. Eur Respir J. 2026. PMID: 41360508. doi:10.1183/13993003.01638-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。